Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Infection and Immunity
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Bacterial Infections

The Vaccine Candidate Substrate Binding Protein SBP2 Plays a Key Role in Arginine Uptake, Which Is Required for Growth of Moraxella catarrhalis

Taketo Otsuka, Charmaine Kirkham, Aimee Brauer, Mary Koszelak-Rosenblum, Michael G. Malkowski, Timothy F. Murphy
B. A. McCormick, Editor
Taketo Otsuka
aDivision of Infectious Diseases, Department of Medicine, University at Buffalo, State University of New York, Buffalo, New York, USA
bClinical and Translational Research Center, University at Buffalo, State University of New York, Buffalo, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charmaine Kirkham
aDivision of Infectious Diseases, Department of Medicine, University at Buffalo, State University of New York, Buffalo, New York, USA
bClinical and Translational Research Center, University at Buffalo, State University of New York, Buffalo, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aimee Brauer
aDivision of Infectious Diseases, Department of Medicine, University at Buffalo, State University of New York, Buffalo, New York, USA
bClinical and Translational Research Center, University at Buffalo, State University of New York, Buffalo, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Koszelak-Rosenblum
dDepartment of Structural Biology, University at Buffalo, State University of New York, Buffalo, New York, USA
eHauptman Woodward Medical Research Institute, Buffalo, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael G. Malkowski
dDepartment of Structural Biology, University at Buffalo, State University of New York, Buffalo, New York, USA
eHauptman Woodward Medical Research Institute, Buffalo, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy F. Murphy
aDivision of Infectious Diseases, Department of Medicine, University at Buffalo, State University of New York, Buffalo, New York, USA
bClinical and Translational Research Center, University at Buffalo, State University of New York, Buffalo, New York, USA
cDepartment of Microbiology and Immunology, University at Buffalo, State University of New York, Buffalo, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. A. McCormick
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/IAI.00799-15
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Moraxella catarrhalis is an exclusively human pathogen that is an important cause of otitis media in children and lower respiratory tract infections in adults with chronic obstructive pulmonary disease. A vaccine to prevent M. catarrhalis infections would have an enormous global impact in reducing morbidity resulting from these infections. Substrate binding protein 2 (SBP2) of an ABC transporter system has recently been identified as a promising vaccine candidate antigen on the bacterial surface of M. catarrhalis. In this study, we showed that SBP1, -2, and -3 individually bind different basic amino acids with exquisite specificity. We engineered mutants that each expressed a single SBP from this gene cluster and showed in growth experiments that SBP1, -2, and -3 serve a nutritional function through acquisition of amino acids for the bacterium. SBP2 mediates uptake of arginine, a strict growth requirement of M. catarrhalis. Adherence and invasion assays demonstrated that SBP1 and SBP3 play a role in invasion of human respiratory epithelial cells, consistent with a nutritional role in intracellular survival in the human respiratory tract. This work demonstrates that the SBPs of an ABC transporter system function in the uptake of basic amino acids to support growth of M. catarrhalis. The critical role of SBP2 in arginine uptake may contribute to its potential as a vaccine antigen.

INTRODUCTION

Moraxella catarrhalis is an exclusively human pathogen whose ecological niche is the human respiratory tract. Nasopharyngeal colonization by M. catarrhalis is common in infancy and decreases with age (1–5). The bacterium is a common cause of disease in two clinical settings: otitis media in children and lower respiratory tract infection in adults with chronic obstructive pulmonary disease (COPD) (6–8).

Approximately 80% of all children experience at least one episode of otitis media (middle ear infection) by the age of 3 years (9). One recent study showed that up to 5% of pediatric outpatients, even without symptoms, had acute otitis media (10). Up to 30% of children develop recurrent acute otitis media (11–13), which may lead to hearing impairment that causes delays in speech and language development (14). A vaccine to prevent these infections would have a major impact on child health by preventing morbidity and reducing health care costs associated with otitis media. M. catarrhalis is a common cause of acute otitis media in children, along with nontypeable Haemophilus influenzae and Streptococcus pneumoniae (6). Studies using PCR to detect bacterial DNA in middle ear fluid reveal that M. catarrhalis plays an even larger role in otitis media than revealed by culture alone (15–18). With the increasing widespread administration of pneumococcal conjugate vaccines globally, patterns of nasopharyngeal colonization in children and the distribution of pathogens causing otitis media are undergoing changes, with M. catarrhalis taking on a more prominent role (19). Thus, a successful vaccine for otitis media will include antigens of the three otopathogens, M. catarrhalis, nontypeable H. influenzae, and S. pneumoniae.

M. catarrhalis is also an important pathogen in adults with COPD, which is a chronic debilitating disease. COPD is the third most common cause of death in the United States and the world. The course of COPD is characterized by intermittent worsening or exacerbations, often caused by bacterial infection of the lower airways (20). M. catarrhalis is the second most common cause of exacerbations, accounting for 2 to 4 million episodes annually in the United States (21). Thus, adults with COPD would also benefit from a vaccine to prevent respiratory tract infections caused by M. catarrhalis.

In view of the compelling public health need for effective methods to prevent otitis media in children and lower respiratory tract infections in adults with COPD, several groups are performing research to develop vaccines to prevent M. catarrhalis infections. We have taken a genome-mining approach to identify conserved proteins that are on the bacterial surface that we are assessing as potential vaccine antigens (22). This work has led to the identification of several surface proteins that induce potentially protective immune responses to M. catarrhalis (23–25).

One such protein, substrate binding protein 2 (SBP2), is predicted to be one of three substrate binding proteins of an ATP-binding cassette (ABC) transporter system encoded by a gene cluster annotated in the M. catarrhalis genome (25). SBP2 is highly conserved among strains, expresses epitopes on the bacterial surface, and induces potentially protective immune responses in the mouse pulmonary clearance model; thus, SBP2 is a promising vaccine antigen. In view of the importance of SBP2 as a vaccine antigen, the present study was undertaken to characterize the function of the ABC transporter and its three substrate binding proteins (SBP1, SBP2, and SBP3) for the bacterial cell and to begin to understand the role of the proteins in the pathogenesis of M. catarrhalis infection. The ABC transporter gene cluster encodes three SBPs that are homologous with amino acid transport substrate binding proteins of other Gram-negative bacteria in the range of 50% identity and 70% similarity (25). In the present study, we show that the gene cluster encodes proteins that individually bind basic amino acids specifically and have a nutritional function through acquisition of essential amino acids for the bacterium. SBP2 mediates uptake of arginine, a strict growth requirement of M. catarrhalis. In addition, at least two of the three substrate binding proteins play a critical role in invasion of human respiratory epithelial cells.

MATERIALS AND METHODS

Bacterial strains and growth.M. catarrhalis strain O35E was provided by Eric Hansen. Single-gene (sbp1, sbp2, and sbp3) knockout mutants and a mutant in which all three sbp genes were knocked out (sbp123) were previously constructed in M. catarrhalis strain O35E (25). M. catarrhalis strains were grown on brain heart infusion (BHI) plates at 35°C with 5% CO2 or in BHI broth with shaking at 37°C. For growth curve experiments, chemically defined medium (CDM), which is a minimal nutrient medium containing the essential elements that M. catarrhalis requires to survive, was used (26).

Purification of recombinant SBP1, SBP2, and SBP3.The sbp1, sbp2, and sbp3 genes were individually cloned into the plasmid pCATCH which allows expression of recombinant lipoproteins in Escherichia coli (27, 28). Purification of the SBP1, SBP2, and SBP3 proteins and assessment of their purity have been described in detail previously (25).

Thermal shift assay.Thermal shift assays were performed using a Stratagene Mx3005P real-time PCR instrument (Stratagene, La Jolla, CA) as previously described (29, 30). Briefly, purified SBP1, SBP2, and SBP3 were studied at a concentration of 10 μg in a 30-μl volume in buffer (0.01 M Tris, 0.15 M NaCl, pH 7.4) to which individual amino acids were added to a final concentration of 1 mM. SYPRO Orange (Sigma) was added as a fluorescence reporter at a 1,000-fold dilution from its stock solution. The change in fluorescence was monitored using a Cy3 filter, with excitation and emission wavelengths of 545 nM and 568 nM, respectively. Temperature was raised from 25°C to 98°C in 0.5°C intervals over the course of 45 min, and fluorescence readings were taken at each interval. The fluorescence data were plotted and normalized, and the first derivative of the curve was calculated to provide the melting temperatures (Tms) using GraphPad Prism, version 5.0, as previously described (29, 31).

Construction of mutants.New mutants were constructed in M. catarrhalis strain O35E in which two of the three genes that encode substrate binding proteins were knocked out so that each new mutant expressed a single SBP. For example, knocking out the sbp1 and sbp2 genes leaves the sbp3 gene which expresses SBP3 as the only substrate binding protein expressed from the gene cluster. Similar mutants that express SBP1 and SBP2 individually were engineered by knocking out the sbp2 and sbp3 genes and the sbp1 and sbp3 gene, respectively.

Mutant construction was accomplished by using overlap extension PCR and homologous recombination as described previously (24, 25, 32). Briefly, the transforming DNA for the mutants was composed of three overlapping fragments that included 1 kb upstream of the gene being knocked out (fragment 1), the nonpolar kanamycin resistance cassette amplified from plasmid pUC18K (33) (fragment 2), and 1 kb downstream of the gene (fragment 3) using the oligonucleotide primers listed in Table S1 in the supplemental material. Mutants were constructed by transformation of strain O35E with a fragment composed of fragments 1, 2, and 3 and selection on BHI plates containing 50 μg/ml of kanamycin. The sbp1 sbp3 mutant was constructed in an sbp1 gene mutant (25) using the spectinomycin resistance cassette amplified from plasmid pSPEC1 as fragment 2 (34). The insert and surrounding sequences of each of the mutants were confirmed by sequence analysis.

Assessment of bacterial growth.Growth curves were performed using a Bioscreen C automated growth curve analysis system (Oy Growth Curves AB Ltd., Helsinki, Finland) according to the manufacturer's instructions. For M. catarrhalis strains, readings of the optical density at 600 nm (OD600) were taken at 30-min intervals with the Bioscreen C system at 37°C with constant shaking (machine settings: fast speed and high amplitude). Five replicate wells were performed for each growth condition. CDM with or without specific amino acid(s) was used for these experiments.

Adherence and invasion assays with respiratory epithelial cells.Quantitative adherence and invasion assays were performed with A549 cells (human type II alveolar lung epithelium; ATCC CCL85) grown in F-12K medium (Gibco, Grand Island, NY) plus 10% fetal bovine serum. Briefly, 2 × 105 A549 cells were seeded into each well of a 24-well tissue culture plate and incubated for ∼48 h, when cells showed confluent growth. Cells were inoculated with broth-grown log-phase bacteria (multiplicity of infection of 1), and the plates were centrifuged at 200 × g for 5 min at room temperature to facilitate contact between bacteria and A549 cells. Plates were incubated for 3 h at 37°C in 5% CO2. Nonadherent cells were removed by gently washing the wells three times with 500 μl of phosphate-buffered saline (PBS). To quantify adherent cells, 200 μl of trypsin (0.25%) was added to each well, and plates were incubated at 37°C for 10 min to remove adherent cells. A 300-μl volume of 1% saponin was applied to each well, and contents were pipetted into microcentrifuge tubes and, after vigorous vortexing, plated in duplicate to perform bacterial cell counts of adherent cells. Medium from infected samples was harvested, diluted in PBS, and cultured on chocolate agar. The colony counts from medium and from cells were added together to calculate the total number of CFU in a sample well. Percent adherence was calculated by dividing the number of CFU per milliliter of adherent bacteria by the number of CFU per milliliter of the total bacteria in the well. Results of assays with mutants were expressed as a percentage of the result with the wild type that was assayed simultaneously. Each experiment was repeated three times.

To measure invasion, gentamicin (100 μg/ml) was added to wells after 3 h of incubation of A549 cells with bacteria. Nonadherent cells were removed by washing, and wells were incubated with gentamicin for 1 h at 37°C in 5% CO2 to kill extracellular bacteria. Cells were removed with trypsin and lysed with saponin as described above to release surviving intracellular bacteria, which were then plated in duplicate. Percent invasion was calculated by dividing the number of CFU per milliliter of intracellular bacteria by the number of CFU per milliliter of the total bacteria in the well. Results of assays with mutants were expressed as a percentage of the result with the wild type that was assayed simultaneously. Each experiment was repeated three times. Statistical significance was determined by performing a two-tailed t test comparing the result with each mutant to that with the wild type.

RESULTS

Binding of amino acids to the SBPs.Thermal shift assays were used to assess the binding of amino acids to purified recombinant SBP1, SBP2, and SBP3. All three proteins showed sharp Tms in buffer in the absence of added amino acids, indicating that the proteins formed a stable conformation (for SBP1, Tm of 59.6°C; for SBP2, Tm of 57.6°C; for SBP3, Tm of 60.7°C) (Table 1). Addition of each of 21 amino acids (20 standard amino acids plus ornithine) individually to the purified proteins and measurement of thermal shifts showed striking specificity in the binding of selected amino acids as indicated by thermal shifts (Table 1). SBP1 showed an upward shift of the Tm of 11.8°C with lysine and no shift with other amino acids. SBP2 showed a shift of 7.0°C with arginine and no shift with other amino acids. SBP3 showed a shift of 8.7°C with ornithine and no shift with other amino acids. We conclude that SBP1 binds lysine, SBP2 binds arginine, and SBP3 binds ornithine with high specificity.

View this table:
  • View inline
  • View popup
TABLE 1

Melting temperatures and results of thermal shift assays with purified SBP1, SBP2, and SBP3

Characterization of expression of SBPs in knockout mutants.To assess the role of each of the three SBPs in the gene cluster under study, mutants that expressed a single SBP in the gene cluster were constructed and characterized. Mutants in which two of the three sbp genes were knocked out each expressed a single SBP. The sbp23 knockout mutant expresses SBP1, the sbp13 knockout mutant expresses SPB2, and the sbp12 mutant expresses SBP3 (Fig. 1). Immunoblot assays with antiserum to each of the purified SBPs show that antiserum raised to the purified protein recognizes its corresponding SBP and that the new mutants express a single SBP (Fig. 1).

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Immunoblot assays of whole-cell lysates of wild-type (WT) and mutant strains as noted for each lane at the bottom of the blots. Immunoblots were probed with antisera raised to purified recombinant SBPs as noted at the top of each panel. Molecular mass markers are noted in kilodaltons on the left. Note that sbp1, sbp2, sbp3, and sbp123 mutants were described by Otsuka et al. (25); they are included here to show each mutant used in the present study.

Role of SBPs in bacterial growth.In order to assess the function of SBPs in the uptake of amino acids for growth of M. catarrhalis, we studied the mutants that individually expressed each one of the three SBPs. For example, a mutant in which spb2 and sbp3 were knocked out expressed only SBP1 and so forth. Arginine is essential for M. catarrhalis growth but can be replaced with ornithine, which is a downstream by-product of arginine metabolism (26, 35). Thermal shift assays demonstrated the primary binding specificities of each of the three proteins: SBP1 binds lysine, SBP2 binds arginine, and SBP3 binds ornithine (Table 1). Table 2 and Fig. S1 in the supplemental material show the results of growth curve experiments with wild-type and mutant strains in CDM that excluded or was supplemented with specific amino acids.

View this table:
  • View inline
  • View popup
TABLE 2

Growth characteristics of O35E and sbp mutants in chemically defined medium

Role of SBP1 in bacterial growth.Growth curves with the sbp23 mutant (expresses SBP1) show that SBP1 has binding affinity for uptake of the three basic amino acids in the order of lysine > arginine > ornithine, based on the following observations (Table 2; see also Fig. S1 in the supplemental material). The sbp123 mutant does not grow in CDM. The sbp23 mutant requires either arginine or ornithine for growth, indicating that SBP1, which has high affinity for lysine, also has the capacity to mediate uptake of arginine and ornithine. However, in medium that contains both lysine and arginine, growth is slower than that of the wild type, consistent with SBP1 binding lysine (not required for growth) with higher affinity than arginine (required for growth). In medium that lacks arginine but contains both lysine and ornithine, the mutant does not grow at all, consistent with SBP1 binding lysine and completely inhibiting binding of ornithine by SBP1. Thus, these results support the conclusion that SBP1 shows binding affinity for uptake of the three amino acids as follows: lysine > arginine > ornithine (Table 2).

Role of SBP2 in bacterial growth.The sbp13 mutant (expresses SBP2) requires arginine in CDM for growth (Table 2; see also Fig. S1 in the supplemental material). Ornithine does not substitute for arginine to support the growth of this mutant, indicating that SBP2 does not mediate the uptake of ornithine. We conclude that SBP2 has binding affinity for arginine uptake but not for ornithine uptake.

Role of SBP3 in bacterial growth.Growth curves for the sbp12 mutant (expresses SBP3) show that SBP3 has affinity for uptake of the three basic amino acids in the order of ornithine > lysine > arginine, based on the following observations. The sbp12 mutant requires ornithine for growth with one exception. Arginine can partially substitute for ornithine as long as there is no lysine in the medium. The sbp12 mutant does not grow in the absence of ornithine when lysine and arginine are present together, consistent with SBP3 having a higher affinity for lysine than for arginine. Thus, we conclude that SBP3 shows binding affinity for uptake of the three amino acids as follows: ornithine > lysine > arginine.

The shapes of growth curves when ornithine is present in the absence of arginine differ from the shapes of the curves in the presence of arginine, even for the wild-type strain (see Fig. S1 in the supplemental material). The culture is slower to reach maximum OD and reaches a higher OD with ornithine present in place of arginine. We speculate that the altered growth pattern is related to the activation of different metabolic pathways required for the processing of ornithine compared to those required for arginine.

Role of SBPs in adherence and invasion of human respiratory epithelial cells.Wild-type and SBP mutant strains were assayed for their capacity to adhere to and invade the human respiratory epithelial cell line A549 (type 2 pneumocytes). In performing the assays, we observed that growth of the sbp2 and sbp123 knockout mutants was impaired under the conditions of this assay, resulting in ∼2-log difference between the mutants and wild type in the number of bacteria in the wells after 3 h. This growth defect is likely due to the critical role that SBP2 plays in uptake of arginine by M. catarrhalis and the differences in relative abundances of nutrients in bacterial medium and cell culture medium. Thus, it was not possible to accurately determine adherence and invasion of the sbp2 and sbp123 mutants as a result of this confounding variable.

There was no difference in adherence of the sbp1 and sbp3 knockout mutants and the wild type to respiratory epithelial cells, indicating that SBP1 and SBP3 played no role in adherence in these assays. In contrast, both sbp1 and sbp3 knockout mutants showed significantly reduced invasion of respiratory epithelial cells compared to that of the wild type (P < 0.005 for both) (Fig. 2). Invasion of the mutants was approximately 40% of the wild-type level. We conclude that SBP1 and SBP3 play a role in invasion of respiratory epithelial cells by M. catarrhalis.

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Results of adherence and invasion assays with the A549 respiratory epithelial cell line. Adherence and invasion are shown as a percentage of the wild-type values. Error bars show standard deviations of three independent experiments. **, P < 0.005 compared to results for the wild type (two-tailed t test).

DISCUSSION

SBP2 of the ABC transporter system that is the focus of the current study was previously identified as a promising vaccine antigen for M. catarrhalis (25). SBP2 is highly conserved among strains and expresses epitopes on the bacterial surface, and these epitopes bind potentially protective antibodies. Furthermore, immunization with recombinant purified SBP2 induces enhanced clearance in the mouse pulmonary clearance model (25). In view of the potential importance of SBP2 as a vaccine candidate, the present study was undertaken to further characterize the SBPs encoded by the ABC transporter gene cluster that encodes SBP2 to better understand their function for the bacterium and to begin to understand their role in pathogenesis. Understanding the function of the vaccine antigen, SBP2, will contribute to vaccine development, for example, by guiding the development of functional assays to assess potentially protective responses.

The ABC transporter gene cluster encodes three SBPs that are homologous with amino acid transport substrate binding proteins of other Gram-negative bacteria in the range of 50% identity and 70% similarity (25). The current study shows the following: (i) that the SBPs in this gene cluster have binding specificity for individual basic amino acids, i.e., lysine (SBP1), arginine (SBP2), and ornithine (SBP3); (ii) that the SBPs function in the uptake of basic amino acids to support growth of M. catarrhalis; and (iii) that SBP1 and -3 are required for optimal intracellular survival in human respiratory epithelial cells. One might speculate that SBP1 and SBP3 facilitate intracellular survival because lysine and ornithine may be limited in the intracellular environment. The observation that a mutant that lacks all three SBPs does not grow in chemically defined medium emphasizes the important function of this transporter in survival of M. catarrhalis in nutritionally depleted environments, including the middle ear, the lower airways, and intracellular environments, all sites where M. catarrhalis causes disease. Collectively, these observations are consistent with the concept that the SBPs in this ABC transporter are nutritional virulence factors that contribute to the capacity of M. catarrhalis to survive in the ecological niche of the human respiratory tract.

M. catarrhalis has a strict growth requirement for arginine (26, 36); thus, this gene cluster, and particularly SBP2 by mediating uptake of arginine, may be especially critical for the bacterium to colonize and infect the human respiratory tract. Most arginine that is present in the human respiratory tract is methylated because it is derived from proteolysis of host proteins (37, 38). The ratio of methylated arginine and l-arginine in the airways is called the “arginine paradox” whereby l-arginine is limited due to intracellular sequestration, competition for arginase, and production of nitric oxide (39, 40). M. catarrhalis requires l-arginine for growth and cannot use methylated arginine, indicating that specific arginine uptake systems are critical for survival in the respiratory tract (36). M. catarrhalis also has an oligopeptide permease transporter system that mediates uptake of arginine-containing peptides (36).

M. catarrhalis invades and survives inside host cells in the human respiratory tract. Heiniger et al. (41) demonstrated that cells in the tonsils and adenoids serve as a reservoir for M. catarrhalis to persist in the human respiratory tract. The observation that SBP1 and SBP3 partially mediate invasion of respiratory epithelial cells suggests that these proteins contribute to persistence of the bacterium. Although we were unable to assess invasion of cells specifically by mutants that did not express SBP2, one might speculate that SBP2 plays a nutritional role in intracellular persistence, given the importance of SBP2 in the viability of the bacterium, particularly in environments where arginine is limited.

The role of SBP2 in uptake of arginine may have important implications for SBP2 as a vaccine antigen. Immunization with SBP2 induces antibodies to surface epitopes; such antibodies may mediate protective responses through complement-mediated bactericidal killing, opsonization for phagocytosis, or the blocking of adherence and invasion. In addition, binding of antibodies to a functionally important surface molecule may inhibit the function of that molecule. In the case of SBP2, blocking the uptake of arginine could be lethal for M. catarrhalis. This scenario is analogous to the observation that inhibition of the glycerophosphodiesterase activity of protein D of H. influenzae is an important element in the protective responses to H. influenzae induced by the pneumococcal conjugate vaccine that has protein D as the carrier protein (42, 43).

The binding specificity of the SBPs indicates that this gene cluster is a lysine-arginine-ornithine (LAO) ABC transporter. The LAO transporters in Escherichia coli, Salmonella enterica serovar Typhimurium, and Pseudomonas aeruginosa each have single substrate binding proteins that bind lysine, arginine, and ornithine (44–48). In contrast, this LAO transporter in M. catarrhalis has three separate SBPs encoded by individual genes. Each SBP has distinct binding affinities (Tables 1 and 2).

Berntsson et al. (49) proposed a classification system for SBPs that is based on structural alignment of publicly available crystal structures of SBPs. LAO SBPs belong to subcluster F-IV, which is a large subgroup of amino acid-binding proteins (49). SBPs in this subcluster often bind other amino acids in addition to their primary substrates, but generally with an affinity an order of magnitude lower. SBP1 and SBP3 of the LAO transporter of M. catarrhalis show this behavior in the experiments assessing their affinities for uptake of amino acids as nutrients (Table 2). In the thermal shift assay, SBP1, -2, and -3 show exquisite binding specificities to their primary substrates (Table 1), whereas growth experiments with mutants that express each of the SBPs individually detected binding to additional amino acids. The different assay systems used to detect binding may account for this difference. Thermal shift assays are performed with purified recombinant proteins, resulting in partial denaturing of the proteins, which affects their binding characteristics. During bacterial growth the proteins are in their native states. Furthermore, growth rate appears to be a more sensitive endpoint than thermal shift, allowing the detection of lower-affinity binding to secondary amino acid substrates.

This work advances our understanding of how M. catarrhalis takes up arginine and other basic amino acids and the important role that this uptake system plays in growth. The capacity of M. catarrhalis to cause infection in protected niches in the human respiratory tract, including the middle ear and the lower airways, depends on the bacterium's ability to survive and multiply in these hostile environments. The critical role of SBP2 in the uptake of arginine, for which M. catarrhalis has a strict growth requirement, may contribute to its potential as a vaccine candidate. Future investigations should be directed at understanding the effect of immune responses on the function of the substrate binding proteins in this ABC transporter and how this may contribute to protective responses.

ACKNOWLEDGMENTS

This work was supported by NIH grants R01 DC012200 (T.F.M.), NIGMS U54 094611 (M.G.M.), and the Uehara Memorial Foundation (T.O.).

FOOTNOTES

    • Received 18 June 2015.
    • Returned for modification 25 August 2015.
    • Accepted 13 November 2015.
    • Accepted manuscript posted online 23 November 2015.
  • Supplemental material for this article may be found at http://dx.doi.org/10.1128/IAI.00799-15.

  • Copyright © 2016, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Faden H,
    2. Harabuchi Y,
    3. Hong JJ, Tonawanda/Williamsville Pediatrics
    . 1994. Epidemiology of Moraxella catarrhalis in children during the first 2 years of life: relationship to otitis media. J Infect Dis 169:1312–1317.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Aniansson G,
    2. Alm B,
    3. Andersson B,
    4. Larsson P,
    5. Nylen O,
    6. Peterson H,
    7. Rigner P,
    8. Svanborg M,
    9. Svanborg C
    . 1992. Nasopharyngeal colonization during the first year of life. J Infect Dis 165(Suppl 1):S38–S42. doi:10.1093/infdis/165-Supplement_1-S38.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Leach AJ,
    2. Boswell JB,
    3. Asche V,
    4. Nienhuys TG,
    5. Mathews JD
    . 1994. Bacterial colonization of the nasopharynx predicts very early onset and persistence of otitis media in Australian Aboriginal infants. Pediatr Infect Dis J 13:983–989. doi:10.1097/00006454-199411000-00009.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Vaneechoutte M,
    2. Verschraegen G,
    3. Claeys G,
    4. Weise B,
    5. Van Den Abeele AM
    . 1990. Respiratory tract carrier rates of Moraxella (Branhamella) catarrhalis in adults and children and interpretation of the isolation of M. catarrhalis from sputum. J Clin Microbiol 28:2674–2680.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Ejlertsen T,
    2. Thisted E,
    3. Ebbesen F,
    4. Olesen B,
    5. Renneberg J
    . 1994. Branhamella catarrhalis in children and adults. A study of prevalence, time of colonisation, and association with upper and lower respiratory tract infections. J Infect 29:23–31.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Murphy TF,
    2. Parameswaran GI
    . 2009. Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis 49:124–131. doi:10.1086/599375.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Su YC,
    2. Singh B,
    3. Riesbeck K
    . 2012. Moraxella catarrhalis: from interactions with the host immune system to vaccine development. Future Microbiol 7:1073–1100. doi:10.2217/fmb.12.80.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Karalus R,
    2. Campagnari A
    . 2000. Moraxella catarrhalis: a review of an important human mucosal pathogen. Microbes Infect 2:547–559. doi:10.1016/S1286-4579(00)00314-2.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Pelton SI,
    2. Pettigrew MM,
    3. Barenkamp SJ,
    4. Godfroid F,
    5. Grijalva CG,
    6. Leach A,
    7. Patel J,
    8. Murphy TF,
    9. Selak S,
    10. Bakaletz LO
    . 2013. Panel 6: vaccines. Otolaryngol Head Neck Surg 148(Suppl 4):E90–E101. doi:10.1177/0194599812466535.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Otsuka T,
    2. Kitami O,
    3. Kondo K,
    4. Ota H,
    5. Oshima S,
    6. Tsuchiya A,
    7. Shirai T,
    8. Fujii K,
    9. Nakemure M,
    10. Shijji Y,
    11. Nakamura H,
    12. Masuda Y,
    13. Komiyana K,
    14. Yoshida K,
    15. Ishikawa Y,
    16. Iwaya A,
    17. Takahashi S,
    18. Okazaki M,
    19. Hotomi M,
    20. Tamanaka N
    . 2013. Incidence survey of acute otitis media in children in Sado Island, Japan—Sado Otitis Media Study (SADOMS). PLoS One 8:e68711. doi:10.1371/journal.pone.0068711.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Teele DW,
    2. Klein JD,
    3. Rosner B, the Greater Boston Otitis Media Study Group
    . 1989. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 160:83–94. doi:10.1093/infdis/160.1.83.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Faden H
    . 2001. The microbiologic and immunologic basis for recurrent otitis media in children. Eur J Pediatr 160:407–413. doi:10.1007/s004310100754.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Poehling KA,
    2. Szilagyi PG,
    3. Grijalva CG,
    4. Martin SW,
    5. LaFleur B,
    6. Mitchel E,
    7. Barth RD,
    8. Nuorti JP,
    9. Griffin MR
    . 2007. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 119:707–715. doi:10.1542/peds.2006-2138.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Teele DW,
    2. Klein JO,
    3. Chase C,
    4. Menyuk P,
    5. Rosner BA, the Greater Boston Otitis Media Study Group
    . 1990. Otitis media in infancy and intellectual ability, school achievement, speech, and language at age 7 years. J Infect Dis 162:685–694. doi:10.1093/infdis/162.3.685.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Hendolin PH,
    2. Markkanen A,
    3. Ylikoski J,
    4. Wahlfors JJ
    . 1997. Use of multiplex PCR for simultaneous detection of four bacterial species in middle ear effusions. J Clin Microbiol 35:2854–2858.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Holder RC,
    2. Kirse DJ,
    3. Evans AK,
    4. Peters TR,
    5. Poehling KA,
    6. Swords WE,
    7. Reid SD
    . 2012. One-third of middle ear effusions from children undergoing tympanostomy tube placement had multiple bacterial pathogens. BMC Pediatr 12:87. doi:10.1186/1471-2431-12-87.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Pumarola F,
    2. Mares J,
    3. Losada I,
    4. Minguella I,
    5. Moraga F,
    6. Tarrago D,
    7. Aguilera U,
    8. Casanovas JM,
    9. Gadea G,
    10. Trias E,
    11. Cenoz S,
    12. Sistiaga A,
    13. Garcia-Corbeira P,
    14. Pircon JY,
    15. Marano C,
    16. Hausdorff WP
    . 2013. Microbiology of bacteria causing recurrent acute otitis media (AOM) and AOM treatment failure in young children in Spain: shifting pathogens in the post-pneumococcal conjugate vaccination era. Int J Pediatr Otorhinolaryngol 77:1231–1236. doi:10.1016/j.ijporl.2013.04.002.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Mills N,
    2. Best EJ,
    3. Murdoch D,
    4. Souter M,
    5. Neeff M,
    6. Anderson T,
    7. Salkeld L,
    8. Ahmad Z,
    9. Mahadevan M,
    10. Barber C,
    11. Brown C,
    12. Walker C,
    13. Walls T
    . 2015. What is behind the ear drum? The microbiology of otitis media and the nasopharyngeal flora in children in the era of pneumococcal vaccination. J Paediatr Child Health 51:300–306. doi:10.1111/jpc.12710.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Revai K,
    2. McCormick DP,
    3. Patel J,
    4. Grady JJ,
    5. Saeed K,
    6. Chonmaitree T
    . 2006. Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics 117:1823–1829. doi:10.1542/peds.2005-1983.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Sethi S,
    2. Murphy TF
    . 2008. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 359:2355–2365. doi:10.1056/NEJMra0800353.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Murphy TF,
    2. Brauer AL,
    3. Grant BJ,
    4. Sethi S
    . 2005. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 172:195–199. doi:10.1164/rccm.200412-1747OC.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Ruckdeschel EA,
    2. Kirkham C,
    3. Lesse AJ,
    4. Hu Z,
    5. Murphy TF
    . 2008. Mining the Moraxella catarrhalis genome: identification of potential vaccine antigens expressed during human infection. Infect Immun 76:1599–1607. doi:10.1128/IAI.01253-07.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Ruckdeschel EA,
    2. Brauer AL,
    3. Johnson A,
    4. Murphy TF
    . 2009. Characterization of proteins Msp22 and Msp75 as vaccine antigens of Moraxella catarrhalis. Vaccine 27:7065–7072. doi:10.1016/j.vaccine.2009.09.062.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Yang M,
    2. Johnson A,
    3. Murphy TF
    . 2011. Characterization and evaluation of the Moraxella catarrhalis oligopeptide permease A as a mucosal vaccine antigen. Infect Immun 79:846–857. doi:10.1128/IAI.00314-10.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Otsuka T,
    2. Kirkham C,
    3. Johnson A,
    4. Jones MM,
    5. Murphy TF
    . 2014. Substrate binding protein SBP2 of a putative ABC transporter as a novel vaccine antigen of Moraxella catarrhalis. Infect Immun 82:3503–3512. doi:10.1128/IAI.01832-14.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Juni E,
    2. Heym GA,
    3. Avery M
    . 1986. Defined medium for Moraxella (Branhamella) catarrhalis. Appl Environ Microbiol 52:546–551.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Cullen PA,
    2. Lo M,
    3. Bulach DM,
    4. Cordwell SJ,
    5. Adler B
    . 2003. Construction and evaluation of a plasmid vector for the expression of recombinant lipoproteins in Escherichia coli. Plasmid 49:18–29. doi:10.1016/S0147-619X(02)00150-6.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Adlowitz DG,
    2. Sethi S,
    3. Cullen P,
    4. Adler B,
    5. Murphy TF
    . 2005. Human antibody response to outer membrane protein G1a, a lipoprotein of Moraxella catarrhalis. Infect Immun 73:6601–6607. doi:10.1128/IAI.73.10.6601-6607.2005.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Koszelak-Rosenblum M,
    2. Krol AC,
    3. Simmons DM,
    4. Goulah CC,
    5. Wroblewski L,
    6. Malkowski MG
    . 2008. His-311 and Arg-559 are key residues involved in fatty acid oxygenation in pathogen-inducible oxygenase. J Biol Chem 283:24962–24971. doi:10.1074/jbc.M804358200.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Murphy TF,
    2. Brauer AL,
    3. Kirkham C,
    4. Johnson A,
    5. Koszelak-Rosenblum M,
    6. Malkowski MG
    . 2013. Role of the zinc uptake ABC transporter of Moraxella catarrhalis in persistence in the respiratory tract. Infect Immun 81:3406–3413. doi:10.1128/IAI.00589-13.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Yeh AP,
    2. McMillan A,
    3. Stowell MH
    . 2006. Rapid and simple protein-stability screens: application to membrane proteins. Acta Crystallogr D Biol Crystallogr 62:451–457. doi:10.1107/S0907444906005233.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Shevchuk NA,
    2. Bryksin AV,
    3. Nusinovich YA,
    4. Cabello FC,
    5. Sutherland M,
    6. Ladisch S
    . 2004. Construction of long DNA molecules using long PCR-based fusion of several fragments simultaneously. Nucleic Acids Res 32:e19. doi:10.1093/nar/gnh014.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Menard R,
    2. Sansonetti PJ,
    3. Parsot C
    . 1993. Nonpolar mutagenesis of the ipa genes defines IpaB, IpaC, and IpaD as effectors of Shigella flexneri entry into epithelial cells. J Bacteriol 175:5899–5906.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Bakaletz LO,
    2. Baker BD,
    3. Jurcisek JA,
    4. Harrison A,
    5. Novotny LA,
    6. Bookwalter JE,
    7. Mungur R,
    8. Munson RS
    . 2005. Demonstration of type IV pilus expression and a twitching phenotype by Haemophilus influenzae. Infect Immun 73:1635–1643. doi:10.1128/IAI.73.3.1635-1643.2005.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Morris SM, Jr
    . 2007. Arginine metabolism: boundaries of our knowledge. J Nutr 137(6 Suppl 2):1602S–1609S.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Jones MM,
    2. Johnson A,
    3. Koszelak-Rosenblum M,
    4. Kirkham C,
    5. Brauer AL,
    6. Malkowski MG,
    7. Murphy TF
    . 2014. Role of the oligopeptide permease ABC transporter of Moraxella catarrhalis in nutrient acquisition and persistence in the respiratory tract. Infect Immun 82:4758–4766. doi:10.1128/IAI.02185-14.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Zakrzewicz D,
    2. Eickelberg O
    . 2009. From arginine methylation to ADMA: a novel mechanism with therapeutic potential in chronic lung diseases. BMC Pulm Med 9:5. doi:10.1186/1471-2466-9-5.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Grasemann H,
    2. Al-Saleh S,
    3. Scott JA,
    4. Shehnaz D,
    5. Mehl A,
    6. Amin R,
    7. Rafii M,
    8. Pencharz P,
    9. Belik J,
    10. Ratjen F
    . 2011. Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with cystic fibrosis. Am J Respir Crit Care Med 183:1363–1368. doi:10.1164/rccm.201012-1995OC.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Dweik RA
    . 2007. The lung in the balance: arginine, methylated arginines, and nitric oxide. Am J Physiol Lung Cell Mol Physiol 292:L15–L17.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Bode-Boger SM,
    2. Scalera F,
    3. Ignarro LJ
    . 2007. The l-arginine paradox: Importance of the l-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther 114:295–306. doi:10.1016/j.pharmthera.2007.03.002.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Heiniger N,
    2. Spaniol V,
    3. Troller R,
    4. Vischer M,
    5. Aebi C
    . 2007. A reservoir of Moraxella catarrhalis in human pharyngeal lymphoid tissue. J Infect Dis 196:1080–1087. doi:10.1086/521194.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Forsgren A,
    2. Riesbeck K,
    3. Janson H
    . 2008. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin Infect Dis 46:726–731. doi:10.1086/527396.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Toropainen M,
    2. Raitolehto A,
    3. Henckaerts I,
    4. Wauters D,
    5. Poolman J,
    6. Lestrate P,
    7. Kayhty H
    . 2008. Pneumococcal Haemophilus influenzae protein D conjugate vaccine induces antibodies that inhibit glycerophosphodiester phosphodiesterase activity of protein D. Infect Immun 76:4546–4553. doi:10.1128/IAI.00418-08.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Celis TF,
    2. Rosenfeld HJ,
    3. Maas WK
    . 1973. Mutant of Escherichia coli K-12 defective in the transport of basic amino acids. J Bacteriol 116:619–626.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Oh BH,
    2. Ames GF,
    3. Kim SH
    . 1994. Structural basis for multiple ligand specificity of the periplasmic lysine-, arginine-, ornithine-binding protein. J Biol Chem 269:26323–26330.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Nikaido K,
    2. Ames GF
    . 1992. Purification and characterization of the periplasmic lysine-, arginine-, ornithine-binding protein (LAO) from Salmonella typhimurium. J Biol Chem 267:20706–20712.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Silva DA,
    2. Bowman GR,
    3. Sosa-Peinado A,
    4. Huang X
    . 2011. A role for both conformational selection and induced fit in ligand binding by the LAO protein. PLoS Comput Biol 7:e1002054. doi:10.1371/journal.pcbi.1002054.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Nishijyo T,
    2. Park SM,
    3. Lu CD,
    4. Itoh Y,
    5. Abdelal AT
    . 1998. Molecular characterization and regulation of an operon encoding a system for transport of arginine and ornithine and the ArgR regulatory protein in Pseudomonas aeruginosa. J Bacteriol 180:5559–5566.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    1. Berntsson RP,
    2. Smits SH,
    3. Schmitt L,
    4. Slotboom DJ,
    5. Poolman B
    . 2010. A structural classification of substrate-binding proteins. FEBS Lett 584:2606–2617. doi:10.1016/j.febslet.2010.04.043.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
The Vaccine Candidate Substrate Binding Protein SBP2 Plays a Key Role in Arginine Uptake, Which Is Required for Growth of Moraxella catarrhalis
Taketo Otsuka, Charmaine Kirkham, Aimee Brauer, Mary Koszelak-Rosenblum, Michael G. Malkowski, Timothy F. Murphy
Infection and Immunity Jan 2016, 84 (2) 432-438; DOI: 10.1128/IAI.00799-15

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Infection and Immunity article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Vaccine Candidate Substrate Binding Protein SBP2 Plays a Key Role in Arginine Uptake, Which Is Required for Growth of Moraxella catarrhalis
(Your Name) has forwarded a page to you from Infection and Immunity
(Your Name) thought you would be interested in this article in Infection and Immunity.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The Vaccine Candidate Substrate Binding Protein SBP2 Plays a Key Role in Arginine Uptake, Which Is Required for Growth of Moraxella catarrhalis
Taketo Otsuka, Charmaine Kirkham, Aimee Brauer, Mary Koszelak-Rosenblum, Michael G. Malkowski, Timothy F. Murphy
Infection and Immunity Jan 2016, 84 (2) 432-438; DOI: 10.1128/IAI.00799-15
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About IAI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #IAIjournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0019-9567; Online ISSN: 1098-5522